tiprankstipranks
Trending News
More News >
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
US Market
Advertisement

Intellia Therapeutics (NTLA) Ownership - Who Owns Intellia Therapeutics?

Compare
4,121 Followers

Intellia Therapeutics (NTLA) Ownership Overview

1.75%17.93%35.45%29.74%15.12%
35.45% Other Institutional Investors
29.74% ETFs
15.12% Public Companies and Individual Investors
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail, and individual investors. Approximately 83.12% of the company’s stock is owned by Institutional Investors, 1.75% is owned by Insiders, and 15.12% is owned by Public Companies and Individual Investors.
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail, and individual investors. Approximately 53.39% of the company’s stock is owned by Institutional Investors, 1.75% is owned by Insiders, and 29.74% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 22, 2025
xxxxxxxxxxxxx
$1003000
Jul 25, 2025
xxxxxxxxxxxxx
$104617
Jul 03, 2025
xxxxxxxxxxxxx
$24905
Jan 07, 2025
xxxxxxxxxxxxx
$16711

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$2202086
Jun 30, 2025
xxxxxxxxxxxxx
$11434857
Jun 30, 2025
xxxxxxxxxxxxx
$25097822
Jun 30, 2025
xxxxxxxxxxxxx
$122107676

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
13,763,763Institution12.82%157,182,173
13,017,876Institution12.13%148,664,144
9,163,907Institution8.54%104,651,818
8,755,646Institution8.16%99,989,477
4,506,252Institution4.20%51,461,398
2,675,674Institution2.49%30,556,197
1,875,487Institution1.75%21,418,062
1,374,922Institution1.28%15,701,609
1,312,521Institution1.22%14,988,990
1,219,068Institution1.14%13,921,757

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
8,755,646Institution8.16%99,989,477
1,374,922Institution1.28%15,701,609
1,312,521Institution1.22%14,988,990
1,031,931Institution0.96%11,784,652
1,029,415Institution0.96%11,755,919
789,686Institution0.74%9,018,214
587,579Institution0.55%6,710,152
585,526Institution0.55%6,686,707
512,085Institution0.48%5,848,011
378,269Institution0.35%4,319,832

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
10,611,388Institution9.89%121,182,051
3,165,412Institution2.95%36,845,396
2,713,202Institution2.53%30,984,767
2,553,396Institution2.38%29,159,782
2,513,157Institution2.34%29,253,147
1,625,912Institution1.51%18,567,915
1,408,200Institution1.31%16,391,448
1,110,099Institution1.03%12,921,552
909,874Institution0.85%10,390,761
587,470Institution0.55%6,708,907

FAQ

Who Owns Intellia Therapeutics (NTLA)?
According to the latest TipRanks data, approximately 35.45% of the company's stock is held by institutional investors, 1.75% is held by insiders, and 15.12% is held by retail investors.
    What percentage of Intellia Therapeutics (NTLA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 35.45% of Intellia Therapeutics (NTLA) stock is held by institutional investors.
      What percentage of Intellia Therapeutics (NTLA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 15.12% of Intellia Therapeutics (NTLA) stock is held by retail investors.
        Who owns the most shares of Intellia Therapeutics (NTLA)?
        ARK owns the most shares of Intellia Therapeutics (NTLA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis